Canadian Pancreatic Cancer Specialist Expects to Open Clinical Trials on Pill that Doubled Survival Time
A global trial found the pill doubled survival in 500 patients, prompting expanded access while the drug awaits full FDA approval.
- On Wednesday, the Food and Drug Administration granted expanded access to daraxonrasib for pancreatic cancer patients, though it remains experimental pending full approval.
- KRAS mutations present in 90% of pancreatic cancers were historically considered "undruggable." A Phase 3 trial of 500 patients showed those taking the daily pill survived more than a year versus six months on chemotherapy alone.
- Medical oncologist Dr. Jennifer Knox independently reviewed the study, published Sunday in the New England Journal of Medicine, calling the results "amazing." The drug works by locking the RAS protein.
- Manufacturer Revolution Medicines has applied to the FDA to license the drug, while it is now available through an expanded access program. Dr. Knox hopes clinical trials will soon open at Princess Margaret Cancer Centre for Canadian patients.
- The drug is being evaluated in colorectal and lung cancer trials, expanding its potential beyond pancreatic cases. Dr. Marc Roth encouraged patients to ask their oncologists about molecular testing to determine drug candidacy.
38 Articles
38 Articles
burlingtontoday.com
Canadian pancreatic cancer specialists expect to open clinical trials on pill that doubled survival time
TORONTO — Oncologists say they're working to quickly get Canadian patients with pancreatic cancer into clinical trials for a new pill that could double their survival time. Dr.
castanet.net
Canadian pancreatic cancer specialist expects to open clinical trials on pill that doubled survival time
The head of pancreatic cancer at Princess Margaret Cancer Centre says she hopes clinical trials for a pill that could double survival time will soon be open to Canadian patients.
Canadian pancreatic cancer specialist expects to open clinical trials on a pill that doubled survival time
The head of pancreatic cancer at Princess Margaret Cancer Centre says she hopes clinical trials for a pill that could double survival time will soon be open to Canadian patients.
Survival in pancreatic cancer has doubled in one study due to the new therapy.
An international team of researchers has succeeded in creating a drug for a hard-to-treat form of cancer that has eluded scientists for decades. Thanks to the new active ingredient, patients with advanced pancreatic cancer lived twice as long as usual.
The plenary sessions of the annual conference of the American Society of Clinical Oncology (ASCO) are the main event of the meeting, which attracts the most attention and stars the most leading studies of the year. A few days ago, in Chicago, one of those sessions was dedicated to presenting the results of a new drug in the form of pancreatic cancer pills. In the words of Rachna Shroff, a hematologist and member of the organizing scientific soci…
Coverage Details
Bias Distribution
- 65% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
